Your browser doesn't support javascript.
loading
Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial.
Powles, Thomas; Durán, Ignacio; van der Heijden, Michiel S; Loriot, Yohann; Vogelzang, Nicholas J; De Giorgi, Ugo; Oudard, Stéphane; Retz, Margitta M; Castellano, Daniel; Bamias, Aristotelis; Fléchon, Aude; Gravis, Gwenaëlle; Hussain, Syed; Takano, Toshimi; Leng, Ning; Kadel, Edward E; Banchereau, Romain; Hegde, Priti S; Mariathasan, Sanjeev; Cui, Na; Shen, Xiaodong; Derleth, Christina L; Green, Marjorie C; Ravaud, Alain.
Affiliation
  • Powles T; Barts Cancer Institute, Experimental Cancer Medicine Centre, Queen Mary University of London, St Bartholomew's Hospital, London, UK. Electronic address: thomas.powles@bartshealth.nhs.uk.
  • Durán I; Institute of Biomedicine of Seville (IBiS), Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Seville, Spain; Institute of Biomedicine of Seville, Seville, Spain.
  • van der Heijden MS; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands.
  • Loriot Y; Département de Médecine Oncologique, Université Paris-Saclay, Gustave Roussy, Villejuif, France.
  • Vogelzang NJ; US Oncology Research, Comprehensive Cancer Centers of Nevada, Las Vegas, NV, USA.
  • De Giorgi U; Istituto Scientifico Romagnolo per lo studio e la Cura dei Tumori IRST IRCCS, Meldola, Italy.
  • Oudard S; Oncology Department, European Georges Pompidou Hospital, René Descartes University, Paris, France.
  • Retz MM; Department of Urology, Klinikum rechts der Isar, Technical University Munich, Munich, Germany.
  • Castellano D; University Hospital 12 de Octubre, Medical Oncology Department CIBER-ONC, Madrid, Spain.
  • Bamias A; National and Kapodistrian University of Athens Alexandra Hospital, Athens, Greece.
  • Fléchon A; Centre Léon Bérard, Lyon, France.
  • Gravis G; Department of Cancer Medicine, Institut Paoli Calmette, Marseille, France.
  • Hussain S; Plymouth University, Peninsula Schools of Medicine and Dentistry, Plymouth University Hospitals NHS Trust, Plymouth, UK.
  • Takano T; Department of Medical Oncology, Toranomon Hospital, Tokyo, Japan.
  • Leng N; Genentech, South San Francisco, CA, USA.
  • Kadel EE; Genentech, South San Francisco, CA, USA.
  • Banchereau R; Genentech, South San Francisco, CA, USA.
  • Hegde PS; Genentech, South San Francisco, CA, USA.
  • Mariathasan S; Genentech, South San Francisco, CA, USA.
  • Cui N; Genentech, South San Francisco, CA, USA.
  • Shen X; Genentech, South San Francisco, CA, USA.
  • Derleth CL; Genentech, South San Francisco, CA, USA.
  • Green MC; Genentech, South San Francisco, CA, USA.
  • Ravaud A; Department of Medical Oncology, Bordeaux University Hospital, Bordeaux, France.
Lancet ; 391(10122): 748-757, 2018 02 24.
Article in En | MEDLINE | ID: mdl-29268948
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma / Urologic Neoplasms / Paclitaxel / Taxoids / Antibodies, Monoclonal / Antineoplastic Agents Type of study: Clinical_trials / Prognostic_studies Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Lancet Year: 2018 Document type: Article Country of publication: United kingdom
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma / Urologic Neoplasms / Paclitaxel / Taxoids / Antibodies, Monoclonal / Antineoplastic Agents Type of study: Clinical_trials / Prognostic_studies Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Lancet Year: 2018 Document type: Article Country of publication: United kingdom